DoW Bone Marrow Failure, Investigator-Initiated Research Award — HT942526BMFRPIIRA

FundingApproximately $1.25 million total program funding; approximately 1 award; $1.25 million total-cost cap per award; maximum 3-year period of performance. No cost sharing required.

DeadlineMandatory preproposal: August 5, 2026 at 5:00 PM Eastern Time. Invitation date: September 16, 2026. Full application: November 4, 2026 at 11:59 PM Eastern Time. Verification ends November 12, 2026 at 5:00 PM Eastern Time.

Last verifiedOctober 7, 2026

Required next actionCurrent-cycle applicants must have submitted the mandatory August 5 preproposal and received an invitation to submit a full application. Verify invitation status, qualified PI leadership, relevant preliminary data, bone marrow failure program alignment, and appropriate translational or clinical-research readiness before preparing the invited application.

Broad Eligibility

Extramural and intramural U.S. Department of War organizations are eligible, including foreign and domestic organizations, for-profit and nonprofit organizations, and public or private entities. Independent investigators at all career levels affiliated with an eligible organization may serve as PI or partnering PI, subject to the program’s application limits. Cost sharing is not required. Current-cycle progression requires a timely mandatory preproposal and invitation.

Atlas Analysis

Atlas Opportunity Score 90/100. Preferred posture: Partner-Led / Already-Preapplied Bone Marrow Failure Research Team. The award requires relevant preliminary data and supports mature translational and clinical research, including IND-enabling work, but does not allow clinical trials. Structural for-profit eligibility does not establish submission readiness; a credible pursuit requires an invited research team with appropriate scientific depth, evidence, facilities, and regulatory capability.

Federal opportunity identifier: HT942526BMFRPIIRA

The FY26 Bone Marrow Failure Research Program Investigator-Initiated Research Award supports studies that further develop mature ideas and key discoveries with potential to advance bone marrow failure research or patient care. Translational and clinical research are allowed, including preclinical studies, human data or anatomical substances, human-subject research, and correlative studies associated with clinical trials, but this mechanism does not support clinical trials. Preliminary data are required, and a partnering Principal Investigator option is available.

Funding: Approximately $1.25 million for about one award, with a $1.25 million total-cost cap and a maximum three-year period of performance. Cost sharing is not required.

Current-cycle deadlines: The mandatory preproposal deadline was August 5, 2026 at 5:00 PM Eastern Time. Invitations are scheduled for September 16, 2026. Invited full applications are due November 4, 2026 at 11:59 PM Eastern Time.

Because the mandatory first-stage deadline has passed, current-cycle support is restricted to teams that submitted a timely preproposal and receive an invitation. New FY26 applicant outreach should not be initiated for this mechanism.

Source verificationOfficial government source · simpler.grants.govAtlas last verified this record October 7, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗